Press-release for stocks

therapeutics crawled date : 2023 - 01 - 05

save search

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
Published: 2023-01-05 (Crawled : 23:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M

Health Technology

| -56.45% | O: -60.18% H: 3.88% C: -3.2%
collaboration therapeutics agreement

Pittsburgh's Carmell Therapeutics is going public via SPAC – Technical.ly
Published: 2023-01-05 (Crawled : 21:00) - spacfeed.com
ATLXD | $8.1 0

n/a

| 17.86% | O: -0.18% H: 8.6% C: 8.6%
LTUM | News | $0.0364 33.16% 230K

Mining, Quarrying, and Oil and ...

| -55.56% | O: 0.0% H: 5.0% C: 1.89%
therapeutics spac

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
Published: 2023-01-05 (Crawled : 20:00) - biospace.com/
QLGN | $0.301 -3.43% -3.55% 30K

Health Technology

| -76.74% | O: -0.44% H: 10.21% C: 10.21%
disease diagnostic therapeutics update platform

Alpha Healthcare Acquisition III Merging with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform, in $328M Deal
Published: 2023-01-05 (Crawled : 20:00) - spacfeed.com
ATLXD | $8.1 0

n/a

| 17.86% | O: -0.18% H: 8.6% C: 8.6%
LTUM | News | $0.0364 33.16% 230K

Mining, Quarrying, and Oil and ...

| -55.56% | O: 0.0% H: 5.0% C: 1.89%
acquisition phase 2

Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member
Published: 2023-01-05 (Crawled : 19:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.99% | O: -3.07% H: 0.0% C: 0.0%
medical therapeutics

Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
Published: 2023-01-05 (Crawled : 19:00) - biospace.com/
ALGS | $0.735 -7.33% -7.9% 140K

Health Technology

| -20.21% | O: 2.13% H: 7.29% C: 3.13%
alg-0550 drug candidate therapeutics

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 TrialA Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options
Published: 2023-01-05 (Crawled : 17:00) - biospace.com/
OVID | $3.245 1.09% 1.08% 180K

Health Technology

| 70.0% | O: -1.05% H: 2.13% C: 2.13%
ov329 treatment rare therapeutics phase 1

BioSpace Releases Exclusive Hotbed Maps
Published: 2023-01-05 (Crawled : 17:00) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -47.01% | O: 0.0% H: 2.99% C: 2.14%

ZyVersa Therapeutics Appoints Three New Board Members
Published: 2023-01-05 (Crawled : 15:00) - prnewswire.com
FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing

| -66.23% | O: 1.82% H: 14.29% C: 2.68%
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -48.13% | O: -0.8% H: 0.52% C: -0.14%
AXGN | $6.51 -0.61% -0.61% 330K

Health Technology

| -33.47% | O: -1.33% H: 7.56% C: 6.95%
therapeutics

Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
Published: 2023-01-05 (Crawled : 14:20) - biospace.com/
ACER | $0.9 -3.61% 420K

Health Technology

| -66.42% | O: 5.22% H: 0.58% C: -0.35%
acer-801 trials therapeutics

Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs™ Programs with Issuance of U.S. Patent
Published: 2023-01-05 (Crawled : 14:20) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M

Health Technology

| -71.16% | O: -0.81% H: 0.93% C: -1.85%
mdna11 patent

LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
Published: 2023-01-05 (Crawled : 14:00) - biospace.com/
TEX | $60.25 0.8% 0.0% 870K

Producer Manufacturing

| 41.33% | O: -0.45% H: 0.94% C: -0.49%
MS | News | $90.66 0.44% 0.07% 8.1M

Finance

| 4.63% | O: -0.87% H: 0.31% C: 0.02%
OZK | $44.93 2.58% 2.52% 1.6M

Finance

| 12.13% | O: -0.75% H: 0.13% C: -1.84%
therapeutics financial

Asher Bio Appoints Independent Director Elaine Sun to Its Board
Published: 2023-01-05 (Crawled : 14:00) - biospace.com/
PCVX | $60.82 0.33% 0.33% 1.3M

Health Technology

| 29.81% | O: -0.13% H: 0.45% C: -1.58%
HALO M | $38.64 2.2% 2.15% 1.3M

Health Technology

| -28.31% | O: -0.19% H: 1.64% C: 0.8%
DVAX | $11.78 3.88% 3.74% 9.3M

Health Technology

| 11.64% | O: -0.66% H: 0.76% C: -1.24%

Sarepta and Catalent Expand Strategic Manufacturing Partnership
Published: 2023-01-05 (Crawled : 14:00) - catalent.com
CTLT | $55.48 -0.57% -0.4% 1.6M

Health Technology

| 19.44% | O: -1.77% H: 1.78% C: 1.18%
SRPT | $115.53 -0.88% -0.9% 640K

Health Technology

| -7.49% | O: 0.71% H: 0.26% C: -3.38%
partnership

TCR² Therapeutics Announces Pipeline Priorities for 2023
Published: 2023-01-05 (Crawled : 14:00) - globenewswire.com
TCRR 4 | $1.48 3.38% 3.9M

Health Technology

| 40.28% | O: 1.42% H: 0.0% C: 0.0%
therapeutics

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Published: 2023-01-05 (Crawled : 14:00) - biospace.com/
CTLT | $55.48 -0.57% -0.4% 1.6M

Health Technology

| 19.44% | O: -1.77% H: 1.78% C: 1.18%
SRPT | $115.53 -0.88% -0.9% 640K

Health Technology

| -7.49% | O: 0.71% H: 0.26% C: -3.38%
partnership candidate commercial agreement duchenne therapy

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
Published: 2023-01-05 (Crawled : 13:20) - globenewswire.com
OVID | $3.245 1.09% 1.08% 180K

Health Technology

| 70.0% | O: -1.05% H: 2.13% C: 2.13%
ov329 trial therapeutics phase 1

Vivos Therapeutics Announces Pricing of $8 Million Private Placement
Published: 2023-01-05 (Crawled : 13:20) - globenewswire.com
VVOS | $2.72 2.26% 2.21% 34K

Health Technology

| 44.68% | O: -15.96% H: 42.41% C: 18.99%
therapeutics